Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics.

Rifabutin can be cautiously implemented as therapy for H. pylori infection due to its interaction with the tuberculosis endemic in Bangladesh. The high susceptibility of furazolidone and sitafloxacin suggests their possible future application in Nepal and Bangladesh.